Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials

(2016) H. Miwa et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

New and Future Drug Development for Gastroesophageal Reflux Disease

(2014) Carla Maradey-Romero et al.   Journal of Neurogastroenterology and Motility

Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients

(2013) Kazuhide Higuchi et al.   INTERNAL MEDICINE

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment

(2011) Ronnie Fass   Clinical Gastroenterology and Hepatology

Systematic Review: Patterns of Proton Pump Inhibitor Use and Adherence in Gastroesophageal Reflux Disease

(2011) A. Pali S. Hungin et al.   Clinical Gastroenterology and Hepatology

Gastro-Oesophageal Reflux Disease

(2011) Tiberiu Hershcovici et al.   DRUGS

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies

(2010) H. El-Serag et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Epidemiology and clinical characteristics of GERD in the Japanese population

(2009) Yasuhiro Fujiwara et al.   JOURNAL OF GASTROENTEROLOGY